Page 18 - Read Online

Page 14 of 15 Brown. Rare Dis Orphan Drugs J. 2025;4:21 https://dx.doi.org/10.20517/rdodj.2025.14

Chinese cohort. J Neurol. 2024;271:1893-900. DOI
41. Kehrer-Sawatzki H, Kluwe L, Salamon J, et al. Clinical characterization of children and adolescents with NF1 microdeletions. Childs
Nerv Syst. 2020;36:2297-310. DOI PubMed PMC
42. Pinna V, Lanari V, Daniele P, et al. p.Arg1809Cys substitution in neurofibromin is associated with a distinctive NF1 phenotype
without neurofibromas. Eur J Hum Genet. 2015;23:1068-71. DOI PubMed PMC
43. Jiang C, McKay RM, Lee SY, et al. Cutaneous neurofibroma heterogeneity: factors that influence tumor burden in neurofibromatosis
type 1. J Invest Dermatol. 2023;143:1369-77. DOI PubMed PMC
44. Upadhyaya M, Huson SM, Davies M, et al. An absence of cutaneous neurofibromas associated with a 3-bp inframe deletion in exon 17
of the NF1 gene (c.2970-2972 delAAT): evidence of a clinically significant NF1 genotype-phenotype correlation. Am J Hum Genet.
2007;80:140-51. DOI PubMed PMC
45. Trevisson E, Morbidoni V, Forzan M, et al. The Arg1038Gly missense variant in the NF1 gene causes a mild phenotype without
neurofibromas. Mol Genet Genomic Med. 2019;7:e616. DOI
46. Lin MJ, Yao H, Vera K, et al. Cutaneous neurofibromas and quality of life in adults with neurofibromatosis type 1. JAMA Dermatol.
2024;160:1091-8. DOI PubMed PMC
47. Thomas L, Spurlock G, Eudall C, et al. Exploring the somatic NF1 mutational spectrum associated with NF1 cutaneous neurofibromas.
Eur J Hum Genet. 2012;20:411-9. DOI PubMed PMC
48. Emmerich D, Zemojtel T, Hecht J, et al. Somatic neurofibromatosis type 1 (NF1) inactivation events in cutaneous neurofibromas of a
single NF1 patient. Eur J Hum Genet. 2015;23:870-3. DOI PubMed PMC
49. Asai A, Karnan S, Ota A, et al. High-resolution 400K oligonucleotide array comparative genomic hybridization analysis of
neurofibromatosis type 1-associated cutaneous neurofibromas. Gene. 2015;558:220-6. DOI
50. Jacks T, Shih TS, Schmitt EM, Bronson RT, Bernards A, Weinberg RA. Tumour predisposition in mice heterozygous for a targeted
mutation in Nf1. Nat Genet. 1994;7:353-61. DOI PubMed
51. Osum SH, Watson AL, Largaespada DA. Spontaneous and engineered large animal models of neurofibromatosis type 1. Int J Mol Sci.
2021;22:1954. DOI PubMed PMC
52. Isakson SH, Rizzardi AE, Coutts AW, et al. Genetically engineered minipigs model the major clinical features of human
neurofibromatosis type 1. Commun Biol. 2018;1:158. DOI PubMed PMC
53. White KA, Swier VJ, Cain JT, et al. A porcine model of neurofibromatosis type 1 that mimics the human disease. JCI Insight.
2018;3:120402. DOI PubMed PMC
54. Mo J, Anastasaki C, Chen Z, et al. Humanized neurofibroma model from induced pluripotent stem cells delineates tumor pathogenesis
and developmental origins. J Clin Invest. 2021;131:139807. DOI PubMed PMC
55. Mazuelas H, Magallón-Lorenz M, Fernández-Rodríguez J, et al. Modeling iPSC-derived human neurofibroma-like tumors in mice
uncovers the heterogeneity of Schwann cells within plexiform neurofibromas. Cell Rep. 2022;38:110385. DOI
56. Liao CP, Pradhan S, Chen Z, Patel AJ, Booker RC, Le LQ. The role of nerve microenvironment for neurofibroma development.
Oncotarget. 2016;7:61500-8. DOI PubMed PMC
57. Wu J, Williams JP, Rizvi TA, et al. Plexiform and dermal neurofibromas and pigmentation are caused by Nf1 loss in desert hedgehog-
expressing cells. Cancer Cell. 2008;13:105-16. DOI PubMed PMC
58. Le LQ, Shipman T, Burns DK, Parada LF. Cell of origin and microenvironment contribution for NF1-associated dermal
neurofibromas. Cell Stem Cell. 2009;4:453-63. DOI PubMed PMC
59. Radomska KJ, Coulpier F, Gresset A, et al. Cellular origin, tumor progression, and pathogenic mechanisms of cutaneous
neurofibromas revealed by mice with Nf1 knockout in boundary cap cells. Cancer Discov. 2019;9:130-47. DOI
60. Brosseau JP, Pichard DC, Legius EH, et al. The biology of cutaneous neurofibromas: consensus recommendations for setting research
priorities. Neurology. 2018;91:S14-20. DOI PubMed PMC
61. Ge LL, Xing MY, Zhang HB, Wang ZC. Neurofibroma development in neurofibromatosis type 1: insights from cellular origin and
schwann cell lineage development. Cancers. 2022;14:4513. DOI PubMed PMC
62. Zheng H, Chang L, Patel N, et al. Induction of abnormal proliferation by nonmyelinating schwann cells triggers neurofibroma
formation. Cancer Cell. 2008;13:117-28. DOI
63. Parrinello S, Noon LA, Harrisingh MC, et al. NF1 loss disrupts Schwann cell-axonal interactions: a novel role for semaphorin 4F.
Genes Dev. 2008;22:3335-48. DOI
64. Chamseddin BH, Hernandez L, Solorzano D, Vega J, Le LQ. Robust surgical approach for cutaneous neurofibroma in
neurofibromatosis type 1. JCI Insight. 2019;5:128881. DOI PubMed PMC
65. Wozniak B, Bove T, Zawada T, Calik J. Treatment of cutaneous neurofibromas in patients with neurofibromatosis type 1. Case Rep
Dermatol. 2023;15:194-201. DOI PubMed PMC
66. Yoshida Y, Sato N, Furumura M, Nakayama J. Treatment of pigmented lesions of neurofibromatosis 1 with intense pulsed-radio
frequency in combination with topical application of vitamin D3 ointment. J Dermatol. 2007;34:227-30. DOI PubMed
67. Quirk B, Olasz E, Kumar S, Basel D, Whelan H. Photodynamic therapy for benign cutaneous neurofibromas using aminolevulinic acid
topical application and 633 nm red light illumination. Photobiomodul Photomed Laser Surg. 2021;39:411-7. DOI PubMed PMC
68. Peltonen S, Jannic A, Wolkenstein P. Treatment of cutaneous neurofibromas with carbon dioxide laser: technique and patient
experience. Eur J Med Genet. 2022;65:104386. DOI PubMed
69. Chamseddin BH, Le LQ. Management of cutaneous neurofibroma: current therapy and future directions. Neurooncol Adv.